European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

被引：1485

作者：

Baccarani, Michele ^{[1
]}

Deininger, Michael W. ^{[2
]}

Rosti, Gianantonio ^{[3
,4
]}

Hochhaus, Andreas ^{[5
]}

Soverini, Simona ^{[3
,4
]}

Apperley, Jane F. ^{[6
]}

Cervantes, Francisco ^{[7
]}

Clark, Richard E. ^{[8
]}

Cortes, Jorge E. ^{[9
]}

Guilhot, Francois ^{[10
]}

Hjorth-Hansen, Henrik ^{[11
,12
]}

Hughes, Timothy P. ^{[13
,14
]}

Kantarjian, Hagop M. ^{[9
]}

Kim, Dong-Wook ^{[15
]}

Larson, Richard A. ^{[16
]}

Lipton, Jeffrey H. ^{[17
]}

Mahon, Francois-Xavier ^{[18
,19
]}

Martinelli, Giovanni ^{[3
,4
]}

Mayer, Jiri ^{[20
,21
]}

Mueller, Martin C. ^{[22
]}

Niederwieser, Dietger ^{[23
]}

Pane, Fabrizio ^{[24
,25
]}

Radich, Jerald P. ^{[26
]}

Rousselot, Philippe ^{[27
]}

Saglio, Giuseppe ^{[28
]}

Saussele, Susanne ^{[22
]}

Schiffer, Charles ^{[29
]}

Silver, Richard ^{[30
]}

Simonsson, Bengt ^{[31
]}

Steegmann, Juan-Luis ^{[32
]}

Goldman, John M. ^{[33
]}

Hehlmann, Ruediger ^{[22
]}

机构：

[1] Univ Bologna, Dept Hematol L&A Seragnoli, S Orsola M Malpighi Hosp, Bologna, Italy

[2] Univ Utah, Div Hematol & Hematol Malignancies, Huntsman Canc Inst, Salt Lake City, UT USA

[3] Univ Bologna, Dept Expt Diagnost & Specialty Med, Bologna, Italy

[4] St Orsola Marcello Malpighi Hosp, Bologna, Italy

[5] Univ Klinikum Jena, Jena, Germany

[6] Univ London Imperial Coll Sci Technol & Med, Ctr Hematol, London, England

[7] Univ Barcelona, Hosp Clin, Inst Invest Biomed August Pi & Sunyer, Barcelona, Spain

[8] Royal Liverpool Univ Hosp, Liverpool, Merseyside, England

[9] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[10] Univ Poitiers, INSERM, Ctr Invest Clin 0802, CHU Poitiers, Poitiers, France

[11] Norwegian Univ Sci & Technol, Dept Hematol, St Olavs Hosp, N-7034 Trondheim, Norway

[12] Norwegian Univ Sci & Technol, Dept Canc Res & Mol Med, N-7034 Trondheim, Norway

[13] SA Pathol, Adelaide, SA, Australia

[14] Univ Adelaide, Adelaide, SA, Australia

[15] Catholic Univ Korea, Dept Hematol, Seoul St Marys Hosp, Seoul, South Korea

[16] Univ Chicago, Chicago, IL 60637 USA

[17] Univ Toronto, Princess Margaret Hosp, Toronto, ON M5S 1A1, Canada

[18] Univ Bordeaux Segalen, Lab Hematol, CHU Bordeaux, Inst Natl Sante & Rech Med 1035, Bordeaux, France

[19] Univ Bordeaux Segalen, Lab Hematopoiese Leucem & Cible Therapeut, Inst Natl Sante & Rech Med 1035, Bordeaux, France

[20] Masaryk Univ, Univ Hosp Brno, Brno, Czech Republic

[21] Masaryk Univ, Cent European Inst Technol, Brno, Czech Republic

[22] Univ Med Mannheim, Med Klin 2, Mannheim, Germany

[23] Univ Leipzig, Dept Hematol & Oncol, D-04109 Leipzig, Germany

[24] Univ Naples Federico II, Dipartimento Med Clin & Chirurg, Naples, Italy

[25] CEINGE Biotecnol Avanzate, Naples, Italy

[26] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA

[27] Univ Versailles St Qentin En Yvelines, Serv Hematol & Oncol, Hop Mignot, Versailles, France

[28] Univ Turin, Dept Oncol, Turin, Italy

[29] Wayne State Univ, Sch Med, Div Med & Oncol, Karmanos Canc Inst, Detroit, MI USA

[30] Weill Cornell Med Coll, New York, NY USA

[31] Univ Uppsala Hosp, Uppsala, Sweden

[32] Hosp Univ Princesa, Serv Hematol, IIS IP, Madrid, Spain

[33] Univ London Imperial Coll Sci Technol & Med, Dept Hematol, London, England

来源：

BLOOD | 2013年 / 122卷 / 06期

关键词：

TYROSINE KINASE INHIBITORS; DIAGNOSED CHRONIC-PHASE; CHRONIC MYELOGENOUS LEUKEMIA; PATIENTS RECEIVING IMATINIB; MAJOR CYTOGENETIC RESPONSE; SUBCUTANEOUS OMACETAXINE MEPESUCCINATE; COMPLETE MOLECULAR REMISSION; ARTERIAL OCCLUSIVE DISEASE; BCR-ABL1 TRANSCRIPT LEVELS; STEM-CELL TRANSPLANTATION;

D O I：

10.1182/blood-2013-05-501569

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Advances in chronic myeloid leukemia treatment, particularly regarding tyrosine kinase inhibitors, mandate regular updating of concepts and management. A European LeukemiaNet expert panel reviewed prior and new studies to update recommendations made in 2009. We recommend as initial treatment imatinib, nilotinib, or dasatinib. Response is assessed with standardized real quantitative polymerase chain reaction and/or cytogenetics at 3, 6, and 12 months. BCR-ABL1 transcript levels <= 10% at 3 months, <1% at 6 months, and <= 0.1% from 12 months onward define optimal response, whereas >10% at 6 months and >1% from 12 months onward define failure, mandating a change in treatment. Similarly, partial cytogenetic response (PCyR) at 3 months and complete cytogenetic response (CCyR) from 6 months onward define optimal response, whereas no CyR (Philadelphia chromosome-positive [Ph1]>95%) at 3 months, less than PCyR at 6 months, and less than CCyR from 12 months onward define failure. Between optimal and failure, there is an intermediate warning zone requiring more frequent monitoring. Similar definitions are provided for response to second-line therapy. Specific recommendations are made for patients in the accelerated and blastic phases, and for allogeneic stem cell transplantation. Optimal responders should continue therapy indefinitely, with careful surveillance, or they can be enrolled in controlled studies of treatment discontinuation once a deeper molecular response is achieved. (Blood. 2013; 122(6):872-884)

引用

页码：872 / 884

页数：13

共 165 条

[1] The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts [J].

Abboud, Camille ;

Berman, Ellin ;

Cohen, Adam ;

Cortes, Jorge ;

DeAngelo, Daniel ;

Deininger, Michael ;

Devine, Steven ;

Druker, Brian ;

Fathi, Amir ;

Jabbour, Elias ;

Jagasia, Madan ;

Kantarjian, Hagop ;

Khoury, Jean ;

Laneuville, Pierre ;

Larson, Richard ;

Lipton, Jeffrey ;

Moore, Joseph O. ;

Mughal, Tariq ;

O'Brien, Susan ;

Pinilla-Ibarz, Javier ;

Quintas-Cardama, Alfonso ;

Radich, Jerald ;

Reddy, Vishnu ;

Schiffer, Charles ;

Shah, Neil ;

Shami, Paul ;

Silver, Richard T. ;

Snyder, David ;

Stone, Richard ;

Talpaz, Moshe ;

Tefferi, Ayalew ;

Van Etten, Richard A. ;

Wetzler, Meir ;

Abruzzese, Elisabetta ;

Apperley, Jane ;

Breccia, Massimo ;

Byrne, Jenny ;

Cervantes, Francisco ;

Chelysheva, Ekaterina ;

Clark, R. E. ;

de Lavallade, Hugues ;

Dyagil, Iryna ;

Gambacorti-Passerini, Carlo ;

Goldman, John ;

Haznedaroglu, Ibrahim ;

Hjorth-Hansen, Henrik ;

Holyoake, Tessa ;

Huntly, Brian ;

le Coutre, Philipp ;

Lomaia, Elza .

BLOOD, 2013, 121 (22) :4439-4442

[2] Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML [J].

Aichberger, Karl J. ;

Herndlhofer, Susanne ;

Schernthaner, Gerit-Holger ;

Schillinger, Martin ;

Mitterbauer-Hohendanner, Gerlinde ;

Sillaber, Christian ;

Valent, Peter .

AMERICAN JOURNAL OF HEMATOLOGY, 2011, 86 (07) :533-539

[3] Same mutation, different allele [J].

Aichberger, Karl J. ;

Fleischman, Angela G. ;

Deininger, Michael W. .

BLOOD, 2009, 114 (14) :2853-2854

[4] How I treat childhood CML [J].

Andolina, Jeffrey R. ;

Neudorf, Steven M. ;

Corey, Seth J. .

BLOOD, 2012, 119 (08) :1821-1830

[5] Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy [J].

Angelini, Sabrina ;

Soverini, Simona ;

Ravegnini, Gloria ;

Barnett, Matt ;

Turrini, Eleonora ;

Thornquist, Mark ;

Pane, Fabrizio ;

Hughes, Timothy P. ;

White, Deborah L. ;

Radich, Jerald ;

Kim, Dong Wook ;

Saglio, Giuseppe ;

Cilloni, Daniela ;

Iacobucci, Ilaria ;

Perini, Giovanni ;

Woodman, Richard ;

Cantelli-Forti, Giorgio ;

Baccarani, Michele ;

Hrelia, Patrizia ;

Martinelli, Giovanni .

HAEMATOLOGICA, 2013, 98 (02) :193-200

[6] Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia [J].

Apperley, Jane F. .

LANCET ONCOLOGY, 2007, 8 (11) :1018-1029

[7] Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial [J].

Apperley, Jane F. ;

Cortes, Jorge E. ;

Kim, Dong-Wook ;

Roy, Lydia ;

Roboz, Gail J. ;

Rosti, Gianantonio ;

Bullorsky, Eduardo O. ;

Abruzzese, Elisabetta ;

Hochhaus, Andreas ;

Heim, Dominik ;

de Souza, Carmino A. ;

Larson, Richard A. ;

Lipton, Jeffrey H. ;

Khoury, H. Jean ;

Kim, Hyeoung-Joon ;

Sillaber, Christian ;

Hughes, Timothy P. ;

Erben, Philipp ;

Van Tornout, Jan ;

Stone, Richard M. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (21) :3472-3479

[8] Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet [J].

Baccarani, Michele ;

Saglio, Giuseppe ;

Goldman, John ;

Hochhaus, Andreas ;

Simonsson, Bengt ;

Appelbaum, Frederick ;

Apperley, Jane ;

Cervantes, Francisco ;

Cortes, Jorge ;

Deininger, Michael ;

Gratwohl, Alois ;

Guilhot, Frangois ;

Horowitz, Mary ;

Hughes, Timothy ;

Kantarjian, Hagop ;

Larson, Richard ;

Niederwieser, Dielger ;

Silver, Richard ;

Hehlmann, Rudiger .

BLOOD, 2006, 108 (06) :1809-1820

[9] A PROSPECTIVE RANDOMIZED STUDY OF IMATINIB 400 MG VS 800 MG AS A FRONTLINE THERAPY IN SOKAL HIGH RISK (HR) PH-POS CHRONIC MYELOID LEUKEMIA (CML) PATIENTS [J].

Baccarani, M. ;

Haznedaroglu, I. ;

Porkka, K. ;

Castagnetti, F. ;

Alberti, D. ;

Alimena, G. ;

Amabile, M. ;

Bostrom, H. ;

Hjorth-Hansen, H. ;

Kairisto, V. ;

Martinelli, G. ;

Nielsen, J. ;

Palandri, F. ;

Pane, F. ;

Rege-Cambrin, G. ;

Russo, D. ;

Saglio, G. ;

Specchia, G. ;

Testoni, N. ;

Weiss-Bjerrum, O. ;

Rosti, G. ;

Simonsson, B. .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 :161-162

[10] Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet [J].

Baccarani, Michele ;

Cortes, Jorge ;

Pane, Fabrizio ;

Niederwieser, Dietger ;

Saglio, Giuseppe ;

Apperley, Jane ;

Cervantes, Francisco ;

Deininger, Michael ;

Gratwohl, Alois ;

Guilhot, Francois ;

Hochhaus, Andreas ;

Horowitz, Mary ;

Hughes, Timothy ;

Kantarjian, Hagop ;

Larson, Richard ;

Radich, Jerald ;

Simonsson, Bengt ;

Silver, Richard T. ;

Goldman, John ;

Hehlmann, Rudiger .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (35) :6041-6051

← 1 2 3 4 5 6 7 8 9 10 →